212 related articles for article (PubMed ID: 34332307)
21. Activity of cefepime/zidebactam (WCK 5222) against Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter baumannii endemic to New York City medical centres.
Khan Z; Iregui A; Landman D; Quale J
J Antimicrob Chemother; 2019 Oct; 74(10):2938-2942. PubMed ID: 31298277
[TBL] [Abstract][Full Text] [Related]
22. Outbreak caused by an ertapenem-resistant, CTX-M-15-producing Klebsiella pneumoniae sequence type 101 clone carrying an OmpK36 porin variant.
Poulou A; Voulgari E; Vrioni G; Koumaki V; Xidopoulos G; Chatzipantazi V; Markou F; Tsakris A
J Clin Microbiol; 2013 Oct; 51(10):3176-82. PubMed ID: 23850951
[TBL] [Abstract][Full Text] [Related]
23.
Karlowsky JA; Hackel MA; Bouchillon SK; Sahm DF
Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32928739
[TBL] [Abstract][Full Text] [Related]
24. Contribution of β-lactamases and porin proteins OmpK35 and OmpK36 to carbapenem resistance in clinical isolates of KPC-2-producing Klebsiella pneumoniae.
Zhang Y; Jiang X; Wang Y; Li G; Tian Y; Liu H; Ai F; Ma Y; Wang B; Ruan F; Rajakumar K
Antimicrob Agents Chemother; 2014; 58(2):1214-7. PubMed ID: 24277031
[TBL] [Abstract][Full Text] [Related]
25. In vitro activity of cefepime/zidebactam (WCK 5222) against Gram-negative bacteria.
Livermore DM; Mushtaq S; Warner M; Vickers A; Woodford N
J Antimicrob Chemother; 2017 May; 72(5):1373-1385. PubMed ID: 28158732
[TBL] [Abstract][Full Text] [Related]
26. High-level carbapenem resistance in a Klebsiella pneumoniae clinical isolate is due to the combination of bla(ACT-1) beta-lactamase production, porin OmpK35/36 insertional inactivation, and down-regulation of the phosphate transport porin phoe.
Kaczmarek FM; Dib-Hajj F; Shang W; Gootz TD
Antimicrob Agents Chemother; 2006 Oct; 50(10):3396-406. PubMed ID: 17005822
[TBL] [Abstract][Full Text] [Related]
27. Characterization of porin expression in Klebsiella pneumoniae Carbapenemase (KPC)-producing K. pneumoniae identifies isolates most susceptible to the combination of colistin and carbapenems.
Hong JH; Clancy CJ; Cheng S; Shields RK; Chen L; Doi Y; Zhao Y; Perlin DS; Kreiswirth BN; Nguyen MH
Antimicrob Agents Chemother; 2013 May; 57(5):2147-53. PubMed ID: 23459476
[TBL] [Abstract][Full Text] [Related]
28. Activity of Ceftazidime-Avibactam Against Clinical Isolates of Klebsiella pneumoniae, Including KPC-Carrying Isolates, Endemic to New York City.
Manning N; Balabanian G; Rose M; Landman D; Quale J
Microb Drug Resist; 2018; 24(1):35-39. PubMed ID: 28590820
[TBL] [Abstract][Full Text] [Related]
29. Multicenter surveillance of
Jean SS; Ko WC; Lu MC; Lee WS; Hsueh PR;
Expert Rev Anti Infect Ther; 2022 Jun; 20(6):941-953. PubMed ID: 34933656
[TBL] [Abstract][Full Text] [Related]
30. Effect of sigma E on carbapenem resistance in OXA-48-producing Klebsiella pneumoniae.
Cremanns M; Lange F; Gatermann SG; Pfennigwerth N
J Antimicrob Chemother; 2022 May; 77(6):1578-1585. PubMed ID: 35265984
[TBL] [Abstract][Full Text] [Related]
31. Molecular analysis of clinical isolates of ceftazidime-avibactam-resistant Klebsiella pneumoniae.
Venditti C; Butera O; Meledandri M; Balice MP; Cocciolillo GC; Fontana C; D'Arezzo S; De Giuli C; Antonini M; Capone A; Messina F; Nisii C; Di Caro A
Clin Microbiol Infect; 2021 Jul; 27(7):1040.e1-1040.e6. PubMed ID: 33775814
[TBL] [Abstract][Full Text] [Related]
32. Characteristics of carbapenem-resistant Enterobacteriaceae isolates from Korea.
Kim SY; Shin J; Shin SY; Ko KS
Diagn Microbiol Infect Dis; 2013 Aug; 76(4):486-90. PubMed ID: 23688521
[TBL] [Abstract][Full Text] [Related]
33. In vitro activity of cefepime/zidebactam (WCK 5222) against recent Gram-negative isolates collected from high resistance settings of Greek hospitals.
Bhagwat SS; Legakis NJ; Skalidis T; Loannidis A; Goumenopoulos C; Joshi PR; Shrivastava R; Palwe SR; Periasamy H; Patel MV; Chatzipanagiotou S;
Diagn Microbiol Infect Dis; 2021 Jul; 100(3):115327. PubMed ID: 33744624
[TBL] [Abstract][Full Text] [Related]
34. Carbapenem and cefoxitin resistance of Klebsiella pneumoniae strains associated with porin OmpK36 loss and DHA-1 β-lactamase production.
Shi W; Li K; Ji Y; Jiang Q; Wang Y; Shi M; Mi Z
Braz J Microbiol; 2013; 44(2):435-42. PubMed ID: 24294234
[TBL] [Abstract][Full Text] [Related]
35. The efflux pump inhibitor phenylalanine-arginine β-naphthylamide (PAβN) increases resistance to carbapenems in Chilean clinical isolates of KPC-producing Klebsiella pneumoniae.
Vera-Leiva A; Carrasco-Anabalón S; Lima CA; Villagra N; Domínguez M; Bello-Toledo H; González-Rocha G
J Glob Antimicrob Resist; 2018 Mar; 12():73-76. PubMed ID: 29275225
[TBL] [Abstract][Full Text] [Related]
36. Outer membrane protein alterations and blaTEM-1 variants: their role in beta-lactam resistance in Klebsiella pneumoniae.
Nelson EC; Segal H; Elisha BG
J Antimicrob Chemother; 2003 Dec; 52(6):899-903. PubMed ID: 14613957
[TBL] [Abstract][Full Text] [Related]
37. In vitro activity of imipenem/relebactam, meropenem/vaborbactam, ceftazidime/avibactam, cefepime/zidebactam and other novel antibiotics against imipenem-non-susceptible Gram-negative bacilli from Taiwan.
Kuo SC; Wang YC; Tan MC; Huang WC; Shiau YR; Wang HY; Lai JF; Huang IW; Lauderdale TL
J Antimicrob Chemother; 2021 Jul; 76(8):2071-2078. PubMed ID: 33956969
[TBL] [Abstract][Full Text] [Related]
38. The Novel β-Lactam Enhancer Zidebactam Augments the
Bhagwat SS; Periasamy H; Takalkar SS; Palwe SR; Khande HN; Patel MV
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670419
[TBL] [Abstract][Full Text] [Related]
39.
Khamnoi P; Jumroon N; Khamphakul J; Chaihongsa N; Santanirand P
Microb Drug Resist; 2023 Sep; 29(9):416-422. PubMed ID: 37405765
[No Abstract] [Full Text] [Related]
40. Reduced Susceptibility to Carbapenems in a Klebsiella pneumoniae Clinical Isolate Producing SCO-1 and CTX-M-15 β-Lactamases Together with OmpK35 and OmpK36 Porin Deficiency.
Venditti C; Butera O; Proia A; Rigacci L; Mariani B; Parisi G; Messina F; Capone A; Nisii C; Di Caro A
Antimicrob Agents Chemother; 2020 Jul; 64(8):. PubMed ID: 32423955
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
